Abstract
Objectives: To evaluate the association between admission hyperglycemia and major adverse cardiovascular events (MACE) within 6 months in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Methods: This was a descriptive cross-sectional study with prospective follow-up. Two hundred patients diagnosed with acute myocardial infarction who underwent percutaneous coronary intervention at the National Heart Institute of Vietnam from September 2022 to September 2023 were enrolled. Admission blood glucose was measured from venous blood immediately after admission, along with other biochemical and laboratory parameters. Patients were followed for 6 months after successful intervention. Major adverse cardiovascular events (MACE) were recorded, including all-cause mortality, recurrent myocardial infarction, stroke, and rehospitalization due to heart failure. Data were analyzed using Stata 14 software. Results: The mean age was 69.02 ± 12.12 years, and 66.5% were male. During the 6-month follow-up, 77 patients (38.5%) experienced MACE. Admission glucose levels were significantly higher in the MACE group compared to the non-MACE group (p < 0.05). Admission hyperglycemia demonstrated predictive value for MACE with an area under the curve (AUC) of 0.576 (p < 0.05). It was an independent risk factor for MACE with a hazard ratio (HR) of 1.82 (95% CI: 1.09–3.01), p < 0.05. Conclusion: Admission hyperglycemia is an independent prognostic factor for major adverse cardiovascular events and all-cause mortality within 6 months in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
